Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
• Late relapse (>2 years from diagnosis) in DLBCL presents unique treatment challenges.
• R-CHOP-like therapy is a standard first-line treatment for DLBCL.

Purpose of the Study:

• To evaluate the efficacy and outcomes of retreatment with R-CHOP-like therapy in patients with late-relapsing DLBCL.
• To identify factors influencing treatment response and survival in this patient population.

Main Methods:

• Retrospective analysis of 65 DLBCL patients treated with curative-intent R-CHOP-like therapy for late relapse.
• Data collected from BC Cancer databases.
• Analysis of patient demographics, disease characteristics, treatment details, and survival outcomes.

Main Results:

• The median age at relapse was 77 years, with a median time of 7.4 years from original diagnosis.
• Overall response rate was 72% (57% complete response) after a median of 5 cycles of R-CHOP-like therapy.
• Two-year progression-free survival was 46% and overall survival was 54%.
• Patients relapsing >5 years from diagnosis showed significantly better time-to-progression (2-year TTP 66% vs 9%).

Conclusions:

• Retreatment with R-CHOP-like therapy is an effective strategy for many patients with late-relapsing DLBCL.
• This approach can lead to durable responses and survival benefits.
• Late relapse timing (>5 years) is associated with improved outcomes, supporting continued curative-intent treatment.